SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Badreddin Edris Sells 20,000 Shares

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) COO Badreddin Edris sold 20,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the sale, the chief operating officer now owns 169,712 shares of the company's stock, valued at approximately $9,203,481.76. This represents a 10.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Badreddin Edris also recently made the following trade(s):

• On Monday, February 10th, Badreddin Edris sold 30,000 shares of SpringWorks Therapeutics stock. The shares were sold at an average price of $53.13, for a total value of $1,593,900.00.

SpringWorks Therapeutics Trading Down 3.4 %

NASDAQ SWTX traded down $1.77 on Friday, hitting $49.55. 2,503,571 shares of the company's stock were exchanged, compared to its average volume of 1,239,927. The stock has a 50-day moving average of $44.41 and a 200-day moving average of $38.84. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The stock has a market cap of $3.71 billion, a price-to-earnings ratio of -14.24 and a beta of 0.76.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The business had revenue of $61.55 million for the quarter, compared to the consensus estimate of $60.53 million. As a group, analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SWTX shares. Evercore ISI boosted their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Guggenheim cut their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. HC Wainwright reiterated a "buy" rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Finally, Wedbush reiterated an "outperform" rating and issued a $81.00 price target on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SpringWorks Therapeutics has an average rating of "Buy" and a consensus target price of $73.20.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Huntington National Bank increased its holdings in shares of SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after buying an additional 192 shares in the last quarter. AlphaQuest LLC increased its holdings in shares of SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after buying an additional 414 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of SpringWorks Therapeutics during the fourth quarter worth $45,000. State of Wyoming increased its holdings in shares of SpringWorks Therapeutics by 39.5% during the fourth quarter. State of Wyoming now owns 1,530 shares of the company's stock worth $55,000 after buying an additional 433 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of SpringWorks Therapeutics during the fourth quarter worth $56,000.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.